标题
Anti-sense oligonucleotide therapies for the treatment of hyperlipidaemia
作者
关键词
-
出版物
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume 16, Issue 9, Pages 1125-1134
出版商
Informa UK Limited
发表日期
2016-06-02
DOI
10.1080/14712598.2016.1196182
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Macrophage miRNAs in atherosclerosis
- (2016) Denuja Karunakaran et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
- Antisense molecules: A new class of drugs
- (2016) Daniel P. Potaczek et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Safety and efficacy of evinacumab, a monoclonal antibody to ANGPTL3, in patients with homozygous familial hypercholesterolemia receiving concomitant lipid-lowering therapies
- (2016) Daniel Gaudet et al. Journal of Clinical Lipidology
- Effects of angiopoietin-like protein 3 deficiency on postprandial lipid and lipoprotein metabolism
- (2016) Ilenia Minicocci et al. JOURNAL OF LIPID RESEARCH
- Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results
- (2016) Xiaohong Yang et al. JOURNAL OF LIPID RESEARCH
- Complex effects of inhibiting hepatic apolipoprotein B100 synthesis in humans
- (2016) Gissette Reyes-Soffer et al. Science Translational Medicine
- Lipoprotein(a)
- (2016) Sotirios Tsimikas Current Opinion in Endocrinology Diabetes and Obesity
- Comparative Renal Toxicopathology of Antisense Oligonucleotides
- (2016) Jeffery A. Engelhardt Nucleic Acid Therapeutics
- Elevated Lipoprotein(a) Levels, LPA Risk Genotypes, and Increased Risk of Heart Failure in the General Population
- (2016) Pia R. Kamstrup et al. JACC-Heart Failure
- Mipomersen, an Antisense Oligonucleotide to Apolipoprotein B-100, Reduces Lipoprotein(a) in Various Populations With HypercholesterolemiaSignificance
- (2015) Raul D. Santos et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- ISIS-ANGPTL3RX, an antisense inhibitor to angiopoietin-like 3, reduces plasma lipid levels in mouse models and in healthy human volunteers
- (2015) T.A. Brandt et al. ATHEROSCLEROSIS
- Antisense-mediated reduction of proprotein convertase subtilisin/kexin type 9 (PCSK9): a first-in-human randomized, placebo-controlled trial
- (2015) Eveline P. van Poelgeest et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Clinical and Preclinical Pharmacokinetics and Pharmacodynamics of Mipomersen (Kynamro®): A Second-Generation Antisense Oligonucleotide Inhibitor of Apolipoprotein B
- (2015) Richard S. Geary et al. CLINICAL PHARMACOKINETICS
- No effect on QT intervals of mipomersen, a 2′-O-methoxyethyl modified antisense oligonucleotide targeting ApoB-100 mRNA, in a phase I dose escalation placebo-controlled study, and confirmed by a thorough QT (tQT) study, in healthy subjects
- (2015) Rosie Z. Yu et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Oligonucleotide therapeutics: chemistry, delivery and clinical progress
- (2015) Vivek K Sharma et al. Future Medicinal Chemistry
- Nucleic acid-sensing TLRs and autoimmunity: novel insights from structural and cell biology
- (2015) Karin Pelka et al. IMMUNOLOGICAL REVIEWS
- MicroRNA-33–dependent regulation of macrophage metabolism directs immune cell polarization in atherosclerosis
- (2015) Mireille Ouimet et al. JOURNAL OF CLINICAL INVESTIGATION
- Mipomersen preferentially reduces small low-density lipoprotein particle number in patients with hypercholesterolemia
- (2015) Raul D. Santos et al. Journal of Clinical Lipidology
- Efficacy and safety of mipomersen in treatment of dyslipidemia: A meta-analysis of randomized controlled trials
- (2015) Raju Panta et al. Journal of Clinical Lipidology
- Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion
- (2015) Yan Wang et al. JOURNAL OF LIPID RESEARCH
- Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans
- (2015) Mark J. Graham et al. JOURNAL OF LIPID RESEARCH
- Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study
- (2015) Sotirios Tsimikas et al. LANCET
- Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
- (2015) Daniel Gaudet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
- (2015) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liver histology during Mipomersen therapy for severe hypercholesterolemia
- (2014) Nikroo Hashemi et al. Journal of Clinical Lipidology
- Discrimination and Net Reclassification of Cardiovascular Risk With Lipoprotein(a)
- (2014) Peter Willeit et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
- (2014) Anders Berg Jørgensen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting APOC3 in the Familial Chylomicronemia Syndrome
- (2014) Daniel Gaudet et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Roles of Individual Mammalian Argonautes in RNA Interference In Vivo
- (2014) Vera M. Ruda et al. PLoS One
- Nucleic acid therapeutics: basic concepts and recent developments
- (2014) Vivek K. Sharma et al. RSC Advances
- The evidence-base for the efficacy of lipoprotein apheresis in combating cardiovascular disease
- (2013) Gilbert R. Thompson ATHEROSCLEROSIS SUPPLEMENTS
- Lipoprotein Apheresis in Patients With Maximally Tolerated Lipid-Lowering Therapy, Lipoprotein(a)-Hyperlipoproteinemia, and Progressive Cardiovascular Disease
- (2013) Josef Leebmann et al. CIRCULATION
- Antisense Oligonucleotide Inhibition of Apolipoprotein C-III Reduces Plasma Triglycerides in Rodents, Nonhuman Primates, and Humans
- (2013) Mark J. Graham et al. CIRCULATION RESEARCH
- Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension
- (2013) Raul D. Santos et al. EUROPEAN HEART JOURNAL
- Extreme Lipoprotein(a) Levels and Improved Cardiovascular Risk Prediction
- (2013) Pia R. Kamstrup et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Elevated Lipoprotein(a) and Risk of Aortic Valve Stenosis in the General Population
- (2013) Pia R. Kamstrup et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial
- (2013) Kevin Fitzgerald et al. LANCET
- Biodegradable Lipids Enabling Rapidly Eliminated Lipid Nanoparticles for Systemic Delivery of RNAi Therapeutics
- (2013) Martin A Maier et al. MOLECULAR THERAPY
- MicroRNAs and lipoproteins: A connection beyond atherosclerosis?
- (2012) Giuseppe Danilo Norata et al. ATHEROSCLEROSIS
- Alipogene tiparvovec: gene therapy for lipoprotein lipase deficiency
- (2012) Anthony S Wierzbicki et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Inhibition of pre-protein convertase serine kexin-9 (PCSK-9) as a treatment for hyperlipidaemia
- (2012) Anthony S Wierzbicki et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- MicroRNA-27b is a regulatory hub in lipid metabolism and is altered in dyslipidemia
- (2012) Kasey C. Vickers et al. HEPATOLOGY
- Antisense inhibition of apoB synthesis with mipomersen reduces plasma apoC-III and apoC-III-containing lipoproteins
- (2012) Jeremy D. Furtado et al. JOURNAL OF LIPID RESEARCH
- The PCSK9 decade
- (2012) Gilles Lambert et al. JOURNAL OF LIPID RESEARCH
- Lipoprotein(a): Medical Treatment Options for an Elusive Molecule
- (2011) Klaus G. Parhofer CURRENT PHARMACEUTICAL DESIGN
- Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia
- (2011) Fatima Akdim et al. EUROPEAN HEART JOURNAL
- Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management
- (2011) M. John Chapman et al. EUROPEAN HEART JOURNAL
- Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis
- (2011) Katey J. Rayner et al. JOURNAL OF CLINICAL INVESTIGATION
- Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides
- (2011) Katey J. Rayner et al. NATURE
- Lipoprotein(a) as a cardiovascular risk factor: current status
- (2010) Børge G. Nordestgaard et al. EUROPEAN HEART JOURNAL
- Lipoprotein(a) levels and long-term cardiovascular risk in the contemporary era of statin therapy
- (2010) Stephen J. Nicholls et al. JOURNAL OF LIPID RESEARCH
- Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial
- (2010) Frederick J Raal et al. LANCET
- Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis
- (2010) Min Jun et al. LANCET
- Future Challenges for Microsomal Transport Protein Inhibitors
- (2009) Anthony Wierzbicki et al. Current Vascular Pharmacology
- Torcetrapib Induces Aldosterone and Cortisol Production by an Intracellular Calcium-Mediated Mechanism Independently of Cholesteryl Ester Transfer Protein Inhibition
- (2009) Xiao Hu et al. ENDOCRINOLOGY
- Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction
- (2009) Pia R. Kamstrup JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effects of CP-532,623 and Torcetrapib, Cholesteryl Ester Transfer Protein Inhibitors, on Arterial Blood Pressure
- (2009) Eileen Blasi et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- The Residual Risk Reduction Initiative: A Call to Action to Reduce Residual Vascular Risk in Patients with Dyslipidemia
- (2008) Jean-Charles Fruchart et al. AMERICAN JOURNAL OF CARDIOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now